{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,28]],"date-time":"2026-03-28T08:28:41Z","timestamp":1774686521354,"version":"3.50.1"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Proteasome inhibitors (PIs), such as bortezomib and calfizomib, were backbone agents in the treatment of multiple myeloma (MM). In this study, we investigated bortezomib interactors in MM cells and identified dihydrolipoamide dehydrogenase (DLD) as a molecular target of bortezomib. DLD catalyzes the oxidation of dihydrolipoamide to form lipoamide, a reaction that also generates NADH. Our data showed that bortezomib bound to DLD and inhibited DLD\u2019s enzymatic function in MM cells. DLD knocked down MM cells (DLD-KD) had decreased levels of NADH. Reduced NADH suppressed assembly of proteasome complex in cells. As a result, DLD-KD MM cells had decreased basal-level proteasome activity and were more sensitive to bortezomib. Since PIs were used in many anti-MM regimens in clinics, we found that high expression of DLD correlated with inferior prognosis of MM. Considering the regulatory role of DLD in proteasome assembly, we evaluated DLD targeting therapy in MM cells. DLD inhibitor CPI-613 showed a synergistic anti-MM effect with bortezomib in vitro and in vivo. Overall, our findings elucidated DLD as an alternative molecular target of bortezomib in MM. DLD-targeting might increase MM sensitivity to PIs.<\/jats:p>","DOI":"10.1038\/s41419-024-06982-2","type":"journal-article","created":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T17:02:48Z","timestamp":1723568568000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Dihydrolipoamide dehydrogenase (DLD) is a novel molecular target of bortezomib"],"prefix":"10.1038","volume":"15","author":[{"given":"Yu","family":"Feng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3041-6440","authenticated-orcid":false,"given":"Jingcao","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jingjing","family":"Wen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linfeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziyue","family":"Mi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianwen","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyao","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyu","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1816-5551","authenticated-orcid":false,"given":"Ting","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5855-4343","authenticated-orcid":false,"given":"Yuhuan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"6982_CR1","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1001\/jama.2022.0003","volume":"327","author":"AJ Cowan","year":"2022","unstructured":"Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA, et al. Diagnosis and management of multiple myeloma. JAMA. 2022;327:464.","journal-title":"JAMA"},{"key":"6982_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122157","volume":"333","author":"Y Feng","year":"2023","unstructured":"Feng Y, Huang J, Wang F, Lin Z, Luo H, Li Q, et al. Methylcrotonyl-CoA carboxylase subunit 1 (MCCA) regulates multidrug resistance in multiple myeloma. Life Sci. 2023;333:122157.","journal-title":"Life Sci"},{"key":"6982_CR3","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1093\/jjco\/hyy108","volume":"48","author":"K Okazuka","year":"2018","unstructured":"Okazuka K, Ishida T. Proteasome inhibitors for multiple myeloma. Jpn J Clin Oncol. 2018;48:785\u201393.","journal-title":"Jpn J Clin Oncol"},{"key":"6982_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2019.100663","volume":"48","author":"S Narayanan","year":"2020","unstructured":"Narayanan S, Cai CY, Assaraf YG, Guo HQ, Cui Q, Wei L, et al. Targeting the ubiquitin-proteasome pathway to overcome anti-cancer drug resistance. Drug Resist Updat. 2020;48:100663.","journal-title":"Drug Resist Updat"},{"key":"6982_CR5","doi-asserted-by":"publisher","first-page":"7451","DOI":"10.1007\/s00018-021-03996-3","volume":"78","author":"IF Duarte","year":"2021","unstructured":"Duarte IF, Caio J, Moedas MF, Rodrigues LA, Leandro AP, Rivera IA, et al. Dihydrolipoamide dehydrogenase, pyruvate oxidation, and acetylation-dependent mechanisms intersecting drug iatrogenesis. Cell Mol Life Sci. 2021;78:7451\u201368.","journal-title":"Cell Mol Life Sci"},{"key":"6982_CR6","doi-asserted-by":"publisher","first-page":"2792","DOI":"10.1111\/cas.14938","volume":"112","author":"J Inoue","year":"2021","unstructured":"Inoue J, Kishikawa M, Tsuda H, Nakajima Y, Asakage T, Inazawa J. Identification of PDHX as a metabolic target for esophageal squamous cell carcinoma. Cancer Sci. 2021;112:2792\u2013802.","journal-title":"Cancer Sci"},{"key":"6982_CR7","doi-asserted-by":"publisher","first-page":"3224","DOI":"10.1096\/fasebj.4.14.2227213","volume":"4","author":"MS Patel","year":"1990","unstructured":"Patel MS, Roche TE. Molecular biology and biochemistry of pyruvate dehydrogenase complexes. FASEB J. 1990;4:3224\u201333.","journal-title":"FASEB J"},{"key":"6982_CR8","doi-asserted-by":"publisher","first-page":"6158","DOI":"10.1073\/pnas.0610618104","volume":"104","author":"NE Babady","year":"2007","unstructured":"Babady NE, Pang YP, Elpeleg O, Isaya G. Cryptic proteolytic activity of dihydrolipoamide dehydrogenase. Proc Natl Acad Sci USA. 2007;104:6158\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6982_CR9","doi-asserted-by":"publisher","first-page":"40232","DOI":"10.1074\/jbc.M111.274415","volume":"286","author":"RA Vaubel","year":"2011","unstructured":"Vaubel RA, Rustin P, Isaya G. Mutations in the dimer interface of dihydrolipoamide dehydrogenase promote site-specific oxidative damages in yeast and human cells. J Biol Chem. 2011;286:40232\u201345.","journal-title":"J Biol Chem"},{"key":"6982_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2023.1159355","volume":"11","author":"B Zhang","year":"2023","unstructured":"Zhang B, Wang Q, Zhang T, Zheng Z, Lin Z, Zhou S, et al. Identification and validation of a novel cuproptosis-related gene signature in multiple myeloma. Front Cell Dev. Biol. 2023;11:1159355.","journal-title":"Front Cell Dev. Biol"},{"key":"6982_CR11","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1002\/hon.2648","volume":"37","author":"ZY Liu","year":"2019","unstructured":"Liu ZY, Tian MY, Deng L, Wang YS, Xing R, Liu H, et al. The potential diagnostic power of CD138+ microparticles from the plasma analysis for multiple myeloma clinical monitoring. Hematolo Oncol. 2019;37:401\u20138.","journal-title":"Hematolo Oncol"},{"key":"6982_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2019.101418","volume":"30","author":"D Shin","year":"2020","unstructured":"Shin D, Lee J, You JH, Kim D, Roh J-L. Dihydrolipoamide dehydrogenase regulates cystine deprivation-induced ferroptosis in head and neck cancer. Redox Biol. 2020;30:101418.","journal-title":"Redox Biol"},{"key":"6982_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-1-4939-7268-5_1","volume":"1664","author":"P Meleady","year":"2018","unstructured":"Meleady P. Two-dimensional gel electrophoresis and 2D-DIGE. Methods Mol Biol. 2018;1664:3\u201314.","journal-title":"Methods Mol Biol"},{"key":"6982_CR14","doi-asserted-by":"publisher","first-page":"7690","DOI":"10.1021\/acs.chemrev.1c00857","volume":"122","author":"DD Vallejo","year":"2022","unstructured":"Vallejo DD, Rojas Ram\u00edrez C, Parson KF, Han Y, Gadkari VV, Ruotolo BT. Mass spectrometry methods for measuring protein stability. Chem Rev. 2022;122:7690\u2013719.","journal-title":"Chem Rev"},{"key":"6982_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2023.105187","volume":"299","author":"HR Powers","year":"2023","unstructured":"Powers HR, Jenjak SE, Volkman BF, Sahoo D. Development and validation of a purification system for functional full-length human SR-B1 and CD36. J Biol Chem. 2023;299:105187.","journal-title":"J Biol Chem"},{"key":"6982_CR16","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-02515-5","volume":"12","author":"Y Feng","year":"2022","unstructured":"Feng Y, Feng X, Jing C, Yu X, Zheng Y, Xu C. The expression and clinical significance of programmed cell death receptor 1 and its ligand in tumor tissues of patients with extranodal nasal NK\/T cell lymphoma. Sci Rep. 2022;12:36.","journal-title":"Sci Rep"},{"key":"6982_CR17","doi-asserted-by":"publisher","first-page":"e157081","DOI":"10.1172\/jci.insight.157081","volume":"7","author":"Y Yang","year":"2022","unstructured":"Yang Y, Gao Y, Huang J, Yang Z, Luo H, Wang F, et al. ISG20L2 suppresses bortezomib antimyeloma activity by attenuating bortezomib binding to PSMB5. JCI Insight. 2022;7:e157081.","journal-title":"JCI Insight"},{"key":"6982_CR18","doi-asserted-by":"publisher","first-page":"517","DOI":"10.3390\/cancers13030517","volume":"13","author":"C Li","year":"2021","unstructured":"Li C, Wendlandt EB, Darbro B, Xu H, Thomas GS, Tricot G, et al. Genetic analysis of multiple myeloma identifies cytogenetic alterations implicated in disease complexity and progression. Cancers. 2021;13:517.","journal-title":"Cancers"},{"key":"6982_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216218","volume":"565","author":"H Luo","year":"2023","unstructured":"Luo H, Feng Y, Wang F, Lin Z, Huang J, Li Q, et al. Combinations of ivermectin with proteasome inhibitors induce synergistic lethality in multiple myeloma. Cancer Lett. 2023;565:216218.","journal-title":"Cancer Lett"},{"key":"6982_CR20","doi-asserted-by":"publisher","first-page":"e08153","DOI":"10.7554\/eLife.08153","volume":"4","author":"D Acosta-Alvear","year":"2015","unstructured":"Acosta-Alvear D, Cho MY, Wild T, Buchholz TJ, Lerner AG, Simakova O, et al. Paradoxical resistance of multiple myeloma to proteasome inhibitors by decreased levels of 19S proteasomal subunits. ELife. 2015;4:e08153.","journal-title":"ELife"},{"key":"6982_CR21","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.critrevonc.2018.05.003","volume":"127","author":"M Wang","year":"2018","unstructured":"Wang M, Law ME, Castellano RK, Law BK. The unfolded protein response as a target for anticancer therapeutics. Crit Rev Oncol\/Hematol. 2018;127:66\u201379.","journal-title":"Crit Rev Oncol\/Hematol"},{"key":"6982_CR22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1073\/pnas.1912531117","volume":"117","author":"X Liu","year":"2020","unstructured":"Liu X, Xiao W, Zhang Y, Wiley SE, Zuo T, Zheng Y, et al. Reversible phosphorylation of Rpn1 regulates 26S proteasome assembly and function. Proc Natl Acad Sci USA. 2020;117:328\u201336.","journal-title":"Proc Natl Acad Sci USA"},{"key":"6982_CR23","doi-asserted-by":"publisher","first-page":"11272","DOI":"10.1074\/jbc.M113.537175","volume":"289","author":"P Tsvetkov","year":"2014","unstructured":"Tsvetkov P, Myers N, Eliav R, Adamovich Y, Hagai T, Adler J, et al. NADH binds and stabilizes the 26S proteasomes independent of ATP. J Biol Chem. 2014;289:11272\u201381.","journal-title":"J Biol Chem"},{"key":"6982_CR24","doi-asserted-by":"publisher","first-page":"9170","DOI":"10.1074\/jbc.275.13.9170","volume":"275","author":"EC Wolff","year":"2000","unstructured":"Wolff EC, Wolff J, Park MH. Deoxyhypusine synthase generates and uses bound NADH in a transient hydride transfer mechanism. J Biol Chem. 2000;275:9170\u20137.","journal-title":"J Biol Chem"},{"key":"6982_CR25","doi-asserted-by":"publisher","first-page":"7800","DOI":"10.3390\/molecules27227800","volume":"27","author":"C Tabolacci","year":"2022","unstructured":"Tabolacci C, Giordano D, Rossi S, Cordella M, D\u2019Arcangelo D, Moschella F, et al. Identification of dihydrolipoamide dehydrogenase as potential target of vemurafenib-resistant melanoma cells. Molecules. 2022;27:7800.","journal-title":"Molecules"},{"key":"6982_CR26","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.2217\/fon-2019-0201","volume":"15","author":"TS Pardee","year":"2019","unstructured":"Pardee TS, Luther S, Buyse M, Powell BL, Cortes J. Devimistat in combination with high dose cytarabine and mitoxantrone compared with high dose cytarabine and mitoxantrone in older patients with relapsed\/refractory acute myeloid leukemia: ARMADA 2000 Phase III study. Future Oncol. 2019;15:3197\u2013208.","journal-title":"Future Oncol"},{"key":"6982_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s00109-011-0849-9","volume":"90","author":"Y Zheng","year":"2011","unstructured":"Zheng Y, Yang J, Qian J, Zhang L, Lu Y, Li H, et al. Novel phosphatidylinositol 3-kinase inhibitor NVP-BKM120 induces apoptosis in myeloma cells and shows synergistic anti-myeloma activity with dexamethasone. J Mol Med. 2011;90:695\u2013706.","journal-title":"J Mol Med"},{"key":"6982_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09392-6","volume":"12","author":"M Perbandt","year":"2022","unstructured":"Perbandt M, Werner N, Prester A, Rohde H, Aepfelbacher M, Hinrichs W, et al. Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as \u03b2-lactamase inhibitors. Sci Rep. 2022;12:5510.","journal-title":"Sci Rep"},{"key":"6982_CR29","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1038\/s41571-020-0341-y","volume":"17","author":"BA Carneiro","year":"2020","unstructured":"Carneiro BA, El-Deiry WS. Targeting apoptosis in cancer therapy. Nat Rev Clin Oncol. 2020;17:395\u2013417.","journal-title":"Nat Rev Clin Oncol"},{"key":"6982_CR30","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/14656566.2019.1707184","volume":"21","author":"K Podar","year":"2020","unstructured":"Podar K, Shah J, Chari A, Richardson PG, Jagannath S. Selinexor for the treatment of multiple myeloma. Expert Opin Pharmacother. 2020;21:399\u2013408.","journal-title":"Expert Opin Pharmacother"},{"key":"6982_CR31","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.1182\/bloodadvances.2022008345","volume":"7","author":"S Findlay","year":"2023","unstructured":"Findlay S, Nair R, Merrill RA, Kaiser Z, Cajelot A, Aryanpour Z, et al. The mitochondrial pyruvate carrier complex potentiates the efficacy of proteasome inhibitors in multiple myeloma. Blood Adv. 2023;7:3485\u2013500.","journal-title":"Blood Adv"},{"key":"6982_CR32","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1016\/j.exphem.2009.04.001","volume":"37","author":"S L\u00fc","year":"2009","unstructured":"L\u00fc S, Yang J, Chen Z, Gong S, Zhou H, Xu X, et al. Different mutants of PSMB5 confer varying bortezomib resistance in T lymphoblastic lymphoma\/leukemia cells derived from the Jurkat cell line. Exp Hematol. 2009;37:831\u20137.","journal-title":"Exp Hematol"},{"key":"6982_CR33","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1182\/blood-2010-02-269514","volume":"117","author":"P P\u00e9rez-Gal\u00e1n","year":"2011","unstructured":"P\u00e9rez-Gal\u00e1n P, Mora-Jensen H, Weniger MA, Shaffer AL, Rizzatti EG, Chapman CM, et al. Bortezomib resistance in mantle cell lymphoma is associated with plasmacytic differentiation. Blood. 2011;117:542\u201352.","journal-title":"Blood"},{"key":"6982_CR34","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1016\/j.ccell.2015.09.010","volume":"28","author":"C Leung-Hagesteijn","year":"2015","unstructured":"Leung-Hagesteijn C, Erdmann N, Cheung G, Keats Jonathan J, Stewart AK, Reece Donna E, et al. Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma. Cancer Cell. 2015;28:541\u20132.","journal-title":"Cancer Cell"},{"key":"6982_CR35","doi-asserted-by":"publisher","first-page":"4415","DOI":"10.1158\/0008-5472.CAN-08-2839","volume":"69","author":"M Milani","year":"2009","unstructured":"Milani M, Rzymski T, Mellor HR, Pike L, Bottini A, Generali D, et al. The role of ATF4 stabilization and autophagy in resistance of breast cancer cells treated with bortezomib. Cancer Res. 2009;69:4415\u201323.","journal-title":"Cancer Res"},{"key":"6982_CR36","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1038\/s41419-018-1219-0","volume":"10","author":"Y Pan","year":"2019","unstructured":"Pan Y, Zhang Y, Liu W, Huang Y, Shen X, Jing R, et al. LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p. Cell Death Dis. 2019;10:106.","journal-title":"Cell Death Dis"},{"key":"6982_CR37","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1111\/j.1432-1033.1986.tb09596.x","volume":"156","author":"G Richarme","year":"1986","unstructured":"Richarme G, Heine HG. Galactose- and maltose-stimulated lipoamide dehydrogenase activities related to the binding-protein-dependent transport of galactose and maltose in toluenized cells of Escherichia coli. Eur J Biochem. 1986;156:399\u2013405.","journal-title":"Eur J Biochem"},{"key":"6982_CR38","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1038\/nsb836","volume":"9","author":"H Ye","year":"2002","unstructured":"Ye H, Cande C, Stephanou NC, Jiang S, Gurbuxani S, Larochette N, et al. DNA binding is required for the apoptogenic action of apoptosis inducing factor. Nat Struct Biol. 2002;9:680\u20134.","journal-title":"Nat Struct Biol"},{"key":"6982_CR39","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.neuint.2017.05.018","volume":"117","author":"A Ambrus","year":"2018","unstructured":"Ambrus A, Adam-Vizi V. Human dihydrolipoamide dehydrogenase (E3) deficiency: Novel insights into the structural basis and molecular pathomechanism. Neurochem Int. 2018;117:5\u201314.","journal-title":"Neurochem Int"},{"key":"6982_CR40","first-page":"5021","volume":"34","author":"K Yoneyama","year":"2014","unstructured":"Yoneyama K, Shibata R, Igarashi A, Kojima S, Kodani Y, Nagata K, et al. Proteomic identification of dihydrolipoamide dehydrogenase as a target of autoantibodies in patients with endometrial cancer. Anticancer Res. 2014;34:5021\u20137.","journal-title":"Anticancer Res"},{"key":"6982_CR41","doi-asserted-by":"publisher","first-page":"5255","DOI":"10.1158\/1078-0432.CCR-14-1019","volume":"20","author":"TS Pardee","year":"2014","unstructured":"Pardee TS, Lee K, Luddy J, Maturo C, Rodriguez R, Isom S, et al. A phase I study of the first-in-class antimitochondrial metabolism agent, CPI-613, in patients with advanced hematologic malignancies. Clin Cancer Res. 2014;20:5255\u201364.","journal-title":"Clin Cancer Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06982-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06982-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06982-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T18:02:54Z","timestamp":1723572174000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-024-06982-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":41,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["6982"],"URL":"https:\/\/doi.org\/10.1038\/s41419-024-06982-2","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,13]]},"assertion":[{"value":"23 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"588"}}